Goettingen, Germany, January 3, 2011 / b3c newswire / – Effective January 1, 2011, the former Millipore executive,
For the Sartorius Group, the new management appointment is a key component in the further strategic and operational development of its laboratory business. With the Bioprocess business significant rise in revenue and profit over the past years, the Executive Board is now increasing focus on the laboratory activities of both Group divisions. The major goals of this initiative are the expansion into strategic, fast growing market segments, the targeted extension of the product portfolio and the reinforcement of direct sales organizations in key markets.
“With Dominique Baly, we are gaining an exceptionally experienced and successful manager for our team. He will give our laboratory business decisive momentum in this fast-evolving market environment to define the future positioning for significant growth,” said CEO and Executive Board Chairman Dr. Joachim Kreuzburg.
“A strong brand, innovative technologies, a dedicated team and uncompromisingly high quality standards all come together at Sartorius. My goal is to leverage all of the above to build a leading laboratory instruments and consumable business across the world,” commented
Dominique Baly is a successful manager in the international laboratory business. He joins Sartorius with more than 35 years of sales and managerial experience for the U.S.-based pharmaceutical supplier Millipore Corporation, which was acquired by Merck KGaA in 2010. From 2005 to 2008, he was President of the $700 millions Bioscience Division. In 2009, he became CEO of Accelerator Sciences LLC, a
Caption: Dominique Baly, President of Sartorius Group Laboratory Business
(For a high resolution picture please right-click the image and select "Save Target As...")
Picture: Lab work using Sartorius products
This press release contains statements about the future development of the Sartorius Group. The content of these statements cannot be guaranteed as they are based on assumptions and estimates that harbor certain risks and uncertainties.
This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version. Furthermore, Sartorius reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.
About Sartorius - www.sartorius.com
The Sartorius Group is a leading international laboratory and process technology provider covering the segments of biotechnology and mechatronics. In 2009, the technology group earned sales revenue of 602.1 million euros. Founded in 1870, the Goettingen-based company currently employs approximately 4,350 persons. The major areas of activity in its biotechnology segment focus on filtration, fluid management, fermentation, purification and laboratory applications. In the mechatronics segment, the company primarily manufactures equipment and systems featuring weighing, measurement and automation technology for laboratory and industrial applications. Key Sartorius customers are from the pharmaceutical, chemical and food and beverage industries and from numerous research and educational institutes of the public sector. Sartorius has its own production facilities in Europe, Asia and
Sartorius Corporate Administration GmbH; 37070
Phone: +49 (0)551/ 308-1686; fax: +49 (0)551/ 308-3572